Leshan Giantstar Farming&Husbandry Valuation
Is 603477 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 603477 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 603477 (CN¥20.9) is trading below our estimate of fair value (CN¥121.06)
Significantly Below Fair Value: 603477 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 603477?
Other financial metrics that can be useful for relative valuation.
| What is 603477's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | n/a |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.7x |
| Enterprise Value/EBITDA | 24.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 603477's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.5x | ||
002041 ShanDongDenghai SeedsLtd | 6.6x | 13.8% | CN¥10.0b |
300087 Winall Hi-tech Seed | 2.5x | 23.3% | CN¥12.0b |
002100 TECON BIOLOGYLTD | 0.5x | 13.1% | CN¥9.8b |
603609 Wellhope Foods | 0.2x | 12.1% | CN¥8.0b |
603477 Leshan Giantstar Farming&Husbandry | 2.1x | 37.8% | CN¥10.9b |
Price-To-Sales vs Peers: 603477 is good value based on its Price-To-Sales Ratio (2.1x) compared to the peer average (2.5x).
Price to Earnings Ratio vs Industry
How does 603477's PE Ratio compare vs other companies in the CN Food Industry?
Price-To-Sales vs Industry: 603477 is expensive based on its Price-To-Sales Ratio (2.1x) compared to the CN Food industry average (1.9x).
Price to Sales Ratio vs Fair Ratio
What is 603477's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.1x |
| Fair PS Ratio | 2.5x |
Price-To-Sales vs Fair Ratio: 603477 is good value based on its Price-To-Sales Ratio (2.1x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CN¥20.90 | CN¥31.31 +49.8% | 35.4% | CN¥47.00 | CN¥23.00 | n/a | 3 |
| Nov ’25 | CN¥20.06 | CN¥31.31 +56.1% | 35.4% | CN¥47.00 | CN¥23.00 | n/a | 3 |
| Oct ’25 | CN¥21.60 | CN¥31.31 +45.0% | 35.4% | CN¥47.00 | CN¥23.00 | n/a | 3 |
| Sep ’25 | CN¥17.87 | CN¥31.31 +75.2% | 35.4% | CN¥47.00 | CN¥23.00 | n/a | 3 |
| Aug ’25 | CN¥21.76 | CN¥46.47 +113.5% | 5.7% | CN¥49.40 | CN¥43.00 | n/a | 3 |
| Jul ’25 | CN¥29.77 | CN¥46.47 +56.1% | 5.7% | CN¥49.40 | CN¥43.00 | n/a | 3 |
| Jun ’25 | CN¥33.03 | CN¥46.47 +40.7% | 5.7% | CN¥49.40 | CN¥43.00 | n/a | 3 |
| May ’25 | CN¥34.82 | CN¥46.47 +33.4% | 5.7% | CN¥49.40 | CN¥43.00 | n/a | 3 |
| Apr ’25 | CN¥36.93 | CN¥46.47 +25.8% | 5.7% | CN¥49.40 | CN¥43.00 | n/a | 3 |
| Mar ’25 | CN¥32.20 | CN¥43.13 +34.0% | 10.3% | CN¥49.40 | CN¥40.00 | n/a | 3 |
| Feb ’25 | CN¥31.18 | CN¥45.47 +45.8% | 8.8% | CN¥49.40 | CN¥40.00 | n/a | 3 |
| Jan ’25 | CN¥37.47 | CN¥45.47 +21.3% | 8.8% | CN¥49.40 | CN¥40.00 | n/a | 3 |
| Dec ’24 | CN¥33.09 | CN¥39.00 +17.9% | 2.6% | CN¥40.00 | CN¥38.00 | n/a | 2 |
| Nov ’24 | CN¥32.29 | CN¥39.00 +20.8% | 2.6% | CN¥40.00 | CN¥38.00 | CN¥20.06 | 2 |
| Oct ’24 | CN¥27.47 | CN¥36.50 +32.9% | 9.6% | CN¥40.00 | CN¥33.00 | CN¥21.60 | 2 |
| Sep ’24 | CN¥26.31 | CN¥36.50 +38.7% | 9.6% | CN¥40.00 | CN¥33.00 | CN¥17.87 | 2 |
| Aug ’24 | CN¥31.38 | CN¥39.00 +24.3% | 2.6% | CN¥40.00 | CN¥38.00 | CN¥21.76 | 2 |
| Jul ’24 | CN¥33.35 | CN¥36.50 +9.4% | 4.1% | CN¥38.00 | CN¥35.00 | CN¥29.77 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.